According to the House Oversight and Government Reform Committee, Medicare Part D makes terrific financial sense...for pharmaceutical companies. A report from the committee shows a $3.7 billion profit in the last two years for pharmaceutical companies due to more favorable reimbursements under Part D -- not a bad return on investment for the $36 million the industry has poured into campaign coffers in that same time period, according to the Center for Responsive Politics.
According to CongressDaily, Medicare Part D (which succeeded in both completely confusing nearly everyone who had to use it, and costing many of them more money) has been a gift to Big Pharma:
"This is an enormous giveaway and it has absolutely no justification," said House Oversight and Government Reform Chairman Henry Waxman . The 100 most-prescribed drugs are manufactured by 29 companies. The 6 million beneficiaries who are eligible for Medicare and Medicaid, known as dual eligibles, earn low incomes, and the federal government pays more than 98 percent of the cost of their prescriptions under Part D, according to the report.